RNA Expression of Cytochrome P450 in Mexican Women with Breast Cancer

  • Bandala, Cindy (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Floriano-Sanchez, E. (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Cardenas-Rodriguez, N. (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Lopez-Cruz, J. (Service of Pathology, Clinica de Especialidades de la Mujer, SEDENA) ;
  • Lara-Padilla, E. (Section of Research and Graduate Studies, Instituto Politecnico Nacional)
  • Published : 2012.06.30


Involvement of cytochrome P450 genes (CYPs) in breast cancer (BCa) may differ between populations, with expression patterns affected by tumorigenesis. This may have an important role in the metabolism of anticancer drugs and in the progression of cancer. The aim of this study was to determine the mRNA expression patterns of four cytochrome P450 genes (CYP2W1, 3A5, 4F11 and 8A1) in Mexican women with breast cancer. Real-time PCR analyses were conducted on 32 sets of human breast tumors and adjacent non-tumor tissues, as well as 20 normal breast tissues. Expression levels were tested for association with clinical and pathological data of patients. We found higher gene expression of CYP2W1, CYP3A5, CYP4F11 in BCa than in adjacent tissues and only low in normal mammary glands in our Mexican population while CYP8A1 was only expressed in BCa and adjacent tissues. We found that Ki67 protein expression was associated with clinicopathological features as well as with CYP2W1, CYP4F11 and CYP8A1 but not with CYP3A5. The results indicated that breast cancer tissues may be better able to metabolize carcinogens and other xenobiotics to active species than normal or adjacent non-tumor tissues.


  1. Abraham JE, Harrington P, Driver KE et al (2009). Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res, 15, 2181-91.
  2. Barnard NJ, Hall PA, Lemoine NR, et al (1987). Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to pathological and clinical variables. J Pathol, 152, 287-95.
  3. Bos CL, Richel DJ, Ritsema T, et al (2004). Prostanoids and prostanoid receptors in signal transduction. Int J Biochem, 36, 1187-205.
  4. Cathcart MC, Reynolds JV, O'Byrne KJ, et al. (2010). The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim Biophys Acta, 1805, 153-66.
  5. Charpin C, Andrac L, Vacheret H, et al (1988). Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki-67) in breast carcinoma tissue sections. Cancer Res, 48, 4368-74.
  6. Choudhary D, Jansson I, Stoilov I, et al (2005). Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys, 436, 50-61.
  7. Cui X, Nelson DR, Strobel HW (2000). A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics, 68, 161-6.
  8. Dhar M, Sepkovic DW, Hirani V, et al (2008). Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J Lipid Res, 49, 612-24.
  9. Fike CD, Aschner JL, Slaughter JC, et al (2011). Pulmonary arterial responses to reactive oxygen species are altered in newborn piglets with chronic hypoxia-induced pulmonary hypertension. Pediatr Res, 70, 136-41.
  10. Floriano-Sanchez E, Cardenas-Rodriguez N, Castro-Marin M, et al (2009). DD3(PCA3) gene expression in cancer and prostatic hiperplasia. Clin Invest Med, 32, 258.
  11. Fradette C, Jlle Batonga J, Teng S, et al (2007). Animal models of acute moderate hypoxia are associated with a downregulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and upregulation of CYP3A6 and P-glycoprotein in liver. Drug Metabolism Dispos, 35, 765-71.
  12. Garrido-Latorre F, Lazcano-Ponce EC, Lopez-Carrillo L, et al (????). Age of natural menopause among women in Mexico city. Int J Gynaecol Obstet, 53, 159-66.
  13. Gerdes J, Lemke H, Baisch H, et al (1984). Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki67. J Immunol, 133, 1710-5.
  14. Guengerich FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17.
  15. Gupta RA, Tan J, Krause WF, et al (2000). Prostacyclin mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA, 97, 13275-80
  16. Hall PA, McKee PH, Menage D, et al. (1993). High levels of p53 protein in UV irradiated normal human skin. Oncogene, 8, 203-7.
  17. Hashizume T, Imaoka S, Mise M, et al (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther, 300, 298-304.
  18. Honn KV, Cicone B, Skoff A (1981). Prostacyclin: a potent antimetastatic agent. Science, 212, 1270-2.
  19. Huang Z, Fasco M J, Figge H L, et al (1996). Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Disp, 24, 899-905.
  20. Huang Z, Guengerich FP, Kaminsky LS (1998). 16-Alphahydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis, 19, 867-72.
  21. Isola JJ, Helin HJ, Helle MJ, et al (1990). Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer, 65, 1180-4.<1180::AID-CNCR2820650525>3.0.CO;2-7
  22. Kalsotra A, Turman CM, Kikuta Y, et al (2004). Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol, 199, 295-304.
  23. Kalsotra A, Strobel HW (2006). Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther, 112, 589-611.
  24. Karlgren M, Miura S, Ingelman-Sundberg M (2005). Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol, 207, 57-61.
  25. Karlgren M, Gomez A, Stark K, et al (2006). Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun, 341, 451-8.
  26. Keith RL, Miller YE, Hudish TM, et al. (2004). Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res, 64, 5897-904.
  27. Kuehl P, Zhang J, Lin Y, et al (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 27, 383-91.
  28. Libby P, Warner SJ, Friedman GB (1988). Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids, J Clin Invest, 81, 487-98.
  29. Locker AP, Birrell K, Bell JA, et al (1992). Ki-67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol, 18, 224-9.
  30. Moncada S, Gryglewski R, Bunting S, et al (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, 263, 663-5.
  31. Murray GI, Patimalla S, Stewart KN, et al (2010). Profiling the expression of cytochrome P450 in breast cancer. Histopathology, 57, 202-11.
  32. Nebert DW (1991). Role of genetics and drug metabolism in human cancer risk. Mutat Res, 247, 267-81.
  33. Needleman P, Isakson PC (1997). The discovery and function of COX-2. J Rheumatol, 49, 6-8.
  34. Nishida CR, Lee M, de Montellano PR (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol, 78, 497-502.
  35. Oyama T, Kagawa N, Kunugita N, et al (2004). Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci, 9, 1967-76.
  36. Pfaffl MW, Horgan GW, Dempfle L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res, 30, 36.
  37. Rakha EA, Chan S (2011). Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol), 23, 587-600.
  38. Railo M, Nordling S, von Boguslawsky K, et al (1993). Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer, 68, 579-83.
  39. Rooseboom M, Commandeur J N, Vermeulen N P (2004). Enzyme catalyzed activation of anticancer prodrugs. Pharmacol Rev, 56, 53-102.
  40. Sistema Nacional de Informacion en Salud, SSa. (2008) [].
  41. Smith G, Stanley LA, Sim E, et al (1995). Metabolic polymorphisms and cancer susceptibility. Cancer Surv, 25, 27-65.
  42. Stearman RS, Grady MC, Nana-Sinkam P, et al (2007). Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol Cancer Res, 5. 295-308.
  43. Torres-Mejía G, Cupul-Uicab LA, Allen B, et al (2005). Comparative study of correlates of early age at menarche among Mexican and Egyptian adolescents. Am J Hum Biol, 17, 654-8.
  44. Tinzl M, Marberger M, Horvath S (2004). DD3(PCA3) RNA analysis in urinea new perspective for detecting prostate cancer. Eur Urol, 46, 182-6.
  45. Ullrich V, Castle L, Weber P (1981). Spectral evidence for the cytochrome P450 nature of prostacyclin synthetase. Biochem Pharmacol, 30, 2033-6.
  46. Uno Y, Matsuno K, Nakamura C, et al (2011). Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci, 3, 487-90.
  47. Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, et al (2007). RNA Expression of Cytochrome P450 in Breast Cancer Patients. Anticancer Res, 27, 4443-50.
  48. Wang LH, Chen L (1996). Organization of the gene encoding human prostacyclin synthase. Biochem Biophys Res Commun, 226, 631-7.
  49. Wang Y, Bell JC, Keeney DS, et al (2010). Gene regulation of CYP4F11 in human keratinocyte HaCaT cells. Drug Metab Dispos, 38, 100-7.
  50. Wiesener B, Hauser-Kronberger CE, Zipperer E, et al (1998). p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. Histopathol, 33, 522-30.
  51. Williams JA, Phillips DH (2000). Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res, 60, 4667-77.
  52. World Health Report. Geneva, WHO (2008). [].
  53. Wrighton SA, Schuetz EG, Thummel KE, et al (2000). The human CYP3A subfamily: practical considerations. Drug Metab Rev, 32, 339-61.
  54. Wu ZL, Sohl CD, Shimada T, et al (2006). Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol, 69, 2007-14.
  55. Xiang L, Liu ZH, Huan Q, et al (2012). Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. Diagn Pathol, 7, 32
  56. Yokoyama C, Yabuki T, Inoue H, et al (1996). Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics, 36, 296-304.

Cited by

  1. Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells vol.36, pp.1, 2013,
  2. CYP3A4 Expression in Breast Cancer and its Association with Risk Factors in Mexican Women vol.15, pp.8, 2014,
  3. Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer vol.16, pp.18, 2016,
  4. The CYP2W1 enzyme: regulation, properties and activation of prodrugs vol.48, pp.3, 2016,